Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and Degarelix in Intermediate and High-risk Prostate Cancer
NCT03080116Phase 2Active, not recruiting
- Sponsor
- UZ Leuven
- Start
- Mar 2019
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by UZ Leuven. Started Mar 2019; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03080116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080116.